In late January, we sat down with Michael Ward from of IVI's newest members, The Alliance for Aging Research. We are so pleased to partner with such a dynamic organization. Thank you so much for speaking with us today. Could you tell us a little bit about the Alliance for Aging Research? [...]
Author: Jennifer Bright, MPA, Executive Director, IVI For decades, we've known that untreated or poorly treated Major Depressive Disorder (MDD) is an enormous burden on individual patients, our health care system, and our society. Despite having this knowledge, there is much work to do in order to support and optimize cost-effective care for patients suffering [...]
IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI's comments raise a broader question about the relevance of the analysis to decision making. IVI writes [...]
In a new Value Blueprints research brief, IVI explores the concept of “structural uncertainty,” an important source of uncertainty that is not generally measured or addressed in cost-effectiveness models. In this research brief, we use the IVI-RA model to demonstrate how different structural assumptions lead to varying cost-effectiveness estimates. As our findings make clear, it [...]
Is Using Centralized Value Assessment to Make Centralized Pricing Decisions the Most Effective Path Forward?
The Pink Sheet article described comment letters to HHS’ drug pricing blueprint recommending that cost-effectiveness analyses by ICER could help promote value-based pricing in government-sponsored insurance. While IVI concurs value assessment is noble, worthwhile and needed, IVI cautions about making centralized pricing decisions based on centralized value assessments within the U.S.’s current decentralized health care [...]
In an op-ed published by Fierce Healthcare, Director of Scientific Communications, Mark Linthicum discusses current shortfalls of value assessment and what is needed to move to value assessment 2.0. Read the full article here.
The Institute for Clinical Economic Review (ICER) recently launched a new pilot program that will allow more extensive evaluation of draft economic models used in ICER's reports. In response to ICER's new program, Mark Linthicum, Director of Scientific Communications for the Innovation and Value Initiative (IVI), commented: "The Innovation and Value Initiative (IVI) is working diligently [...]
In a new commentary for STAT News, Anupam Jena (part of IVI's scientific advisory group) and Dana Goldman discuss the advantages of value-based pricing, pointing out several of the key challenges that complicate the application of health technology assessments. Jena and Goldman make the case that more transparency is needed and that an open-source model [...]
IVI released the research protocol for its first project, which examines the quality of evidence and methods used in cost-effectiveness analysis (CEA) in healthcare. The research protocol is available here. This is the first research project in a series that will look at issues of relevance to policy, value assessment practices or methods, economic questions related [...]
In a recent post on the IVI-sponsored Health Affairs featured blog series, Peter Neumann and James Baumgardner addresses cost effectiveness analysis as applied across different types of of healthcare interventions, and the disproportionate emphasis placed on pharmaceuticals relative to overall healthcare spending. Neumann and Baumgardner outline some reasons why surgical CEAs are more challenging that drug CEAs, [...]